Nih
Nih funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
NIH R01 Clinical Trial Required Parent NOFO (PA-25-305): 2026/2027 Guide
Parent NIH Research Project Grant (R01) mechanism requiring a clinical trial, with recurring NIH submission cycles through mid-2028 and 2027 planning-relevant deadlines.
NIH RFA-CA-27-020: Advanced Development of Informatics Technologies for Cancer Research and Management (U24)
RFA-CA-27-020 invites advanced development and dissemination of mature cancer informatics technologies through a U24 cooperative agreement, with NCI committing approximately $2.6M in FY2027 for about three awards and a maximum direct cost of $600,000 per project year.
NIH RFA-DA-25-024: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
NIH NIDA RFA-DA-25-024 supports high-priority research at the intersection of HIV and substance use, including prevention, treatment, cure, and implementation work with R01 funding flexibility and clinical trials optional.
NIH RFA-DA-25-060: High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
NIH NIDA RM1 funding for interdisciplinary teams studying HIV and substance use, prioritizing ambitious team-based proposals with a single transformative goal and up to five years of support.
NIH RFA-DK-26-310: Diabetes Research Centers (P30 Clinical Trial Optional)
RFA-DK-26-310 supports U.S.-based Diabetes Research Centers (P30) with interdisciplinary core structures, including clinical and translational work, pilot and feasibility funding, and an enrichment framework.
NIH RFA-HL-26-018: CATALYZE Product Definition for Small-Molecule Biologic Combination Therapies
A National Heart, Lung, and Blood Institute RFA to fund short-cycle R33 projects that de-risk combination therapy platforms by producing a clear translational product plan from preclinical or early clinical work.
NIH RFA-NS-26-001: Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
This NIH opportunity funds research that uses expanded-access data from investigational ALS treatments to support studies in patient populations that cannot enter ongoing clinical trials, with $40,000,000 in FY 2026/27 program funding and a four-award cap for the cycle.
NIH RFA-OD-24-011: NIH Research Software Engineer (RSE) Award (R50)
NIH’s Research Software Engineer Award (RFA-OD-24-011) funds up to $300,000 in direct costs over up to three years for full-time, non-tenure-track software engineers who support NIH-funded biomedical research through reproducible software development.
NIH SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional): PAR-27-098
A late-stage small business commercialization bridge for U.S. NIH SBIR or STTR Phase II projects that need outsourced technical development, clinical studies, or market-readiness work before full commercialization.
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional): PA-27-102
Parent STTR NOFO for U.S. small businesses, supports Phase I, Phase II, Direct to Phase II, and Fast-Track tracks with NIH-partnering research projects and optional clinical-trial scope in 2026/2027.